Capturing Native GPCR Structures to Accelerate Drug Discovery

• Incorporating wild-type GPCRs into nanomembrane particles to facilitate the discovery of small molecules, antibodies, and peptides
• Enabling the study of GPCR oligomerisation, comparing results from recombinant versus endogenously expressed receptors
• Discovering how combining structural biology with antibody discovery in a CXCR4- focused study led to the identification of promising therapeutic candidates

Speakers:

Robin Löving

Chief Scientific Officer

Salipro Biotech